Clinical Efficacy and Safety of Tolterodine Compared to Placebo in Detrusor Overactivity

Millard, R. J.; Tuttle, John P.; Moore, Kate H.; Susset, Jacques G.; Clarke, B.; Dwyer, Peter; Davis, Bradley E.

doi:10.1097/00005392-199905000-00036

Cited by 25 publications

(26 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the efficacy of tolterodine in patients with MI was similar to that in a parallel cohort of patients with UI alone, and was in line with earlier studies with tolterodine in patients with OAB [6,8,9,11,13]. From these findings, initial treatment with tolterodine therefore appears warranted for patients reporting mixed symptoms of stress and UI, provided other local or metabolic pathological causes of such symptoms have been excluded.…”

Section: Discussionsupporting

confidence: 84%

Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone

2003

View full text Add to dashboard Cite

patients were treated with tolterodine twice daily for 16 weeks. The two groups were compared for incontinence episodes/24 h, voiding frequency, nocturia episodes and pad usage after 16 weeks of treatment. RESULTSAfter 16 weeks the median changes from baseline for all voiding variables were statistically significant for the MI and the UI groups ( P < 0.001), with no apparent significant between-group differences. The median percentage reduction in incontinence episodes from baseline was 67% for the MI and 75% for the UI groups ( P = 0.39). 'Dry' rates for the MI and UI groups at the end of the study were 39% (66/171) and 44% (243/ 552), respectively, whilst 24% of patients in each group (MI 40/170; UI 130/551) achieved a voiding pattern of <8 voids/24 h. 'Cure' rates for nocturia and the reduction in the number of patients not using pads used were also similar between the groups.

show abstract

Section: Discussionsupporting

confidence: 84%

Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone

2003

View full text Add to dashboard Cite

show abstract

“…These observations were in accordance with earlier findings established for predominantly Caucasian populations. [11][12][13]16 Tolterodine was well tolerated in the present study, and was significantly better tolerated than oxybutynin. The overall incidence of adverse events was significantly lower in patients receiving tolterodine than in those treated with oxybutynin, which may explain the lower rate of withdrawal due to adverse events among tolterodine recipients (10% vs 16% on oxybutynin).…”

Section: Discussionsupporting

confidence: 49%

Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

et al. 2002

View full text Add to dashboard Cite

Background : This double-blind, multicenter study compared the efficacy and tolerability of tolterodine (Pharmacia, Los Angeles, USA) with that of oxybutynin (Alza, Palo Alto, USA) in Asian patients with overactive bladder. Methods : Two-hundred-and-twenty-eight adults with overactive bladder symptoms were randomized to receive tolterodine 2 mg twice daily (bid) ( n = 112) or oxybutynin 5 mg bid ( n = 116). After 8 weeks' treatment, changes in micturition diary variables, patients' perception of treatment benefit, and tolerability endpoints were determined. Results : The mean ( ± SD) number of micturitions/24 h decreased by 2.6 ± 2.9 ( − 21%) with tolterodine and 1.8 ± 4.2 ( − 15%) with oxybutynin (both P = 0.0001 vs baseline). The mean number of incontinence episodes/24 h decreased by 2.2 ± 2.3 ( − 85%) in the tolterodine group and by 1.4 ± 1.8 ( − 58%) in the oxybutynin group (both P = 0.0001 vs baseline). Patient perception of treatment benefit was over 70% in each treatment group. Adverse events were significantly lower in the tolterodine group compared with oxybutynin-treated patients (55% vs 82%; P = 0.001). Dry mouth was reported by significantly fewer patients on tolterodine, compared with oxybutynin (35% vs 63%; P = 0.001) and withdrawals due to adverse events were lower in the tolterodine group than with those treated with oxybutynin (10% vs 16%). There were no safety concerns. Conclusions : Tolterodine 2 mg bid is equally or more effective than oxybutynin 5 mg bid in the treatment of Asian patients with overactive bladder, and shows significantly better tolerability. This may enhance compliance during long-term treatment.

show abstract

“…16 Tolterodine, a relatively new antimuscarinic agent, was developed specifically for the treatment of OAB. [17][18][19][20][21][22][23][24][25] A study of 714 patients with OAB revealed that immediate-release tolterodine 2 mg twice/day was effective, but 41% of the patients reported dry mouth. 20 Similar to oxybutynin, extended-release tolterodine improved efficacy of reducing urge incontinence episodes and lowered the frequency of dry mouth compared with the immediate-release formulation.…”

mentioning

confidence: 99%

Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder

Malone

Armstrong

2006

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Clinical Efficacy and Safety of Tolterodine Compared to Placebo in Detrusor Overactivity

Abstract: Tolterodine administration resulted in a significant decrease in the frequency of voiding and improved voided volume but it was seldom associated with troublesome or severe side effects.

Cited by 25 publications

References 7 publications

Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone

Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone

Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder

Contact Info

Product

Resources

About